Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Details on Person Baselga, J

Class:Id	Person:198815
_displayName	Baselga, J
_timestamp	2007-07-05 13:29:00
created	[InstanceEdit:198855] D'Eustachio, P, 2007-07-05 13:28:49
firstname	Jose
initial	J
surname	Baselga
(author)	[LiteratureReference:198839] Vitamin C crosses the blood-brain barrier in the oxidized form through glucose transporters [LiteratureReference:204238] Proteomic identification of desmoglein 2 and activated leukocyte cell adhesion molecule as substrates of ADAM17 and ADAM10 by difference gel electrophoresis [LiteratureReference:1605816] The cytoplasmic carboxy-terminal amino acid determines the subcellular localization of proTGF-(alpha) and membrane type matrix metalloprotease (MT1-MMP) [LiteratureReference:2179322] USP15 stabilizes TGF-? receptor I and promotes oncogenesis through the activation of TGF-? signaling in glioblastoma [LiteratureReference:2399890] NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations [LiteratureReference:3004684] PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition [LiteratureReference:9646787] Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2) [LiteratureReference:9646931] Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients [LiteratureReference:9691766] Inhibition of Bruton tyrosine kinase in patients with severe COVID-19
[Change default viewing format]

No pathways have been reviewed or authored by Baselga, J (198815)